A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis

Summary

Study to evaluate pharmacokinetics, efficacy, safety and immunogenicity of multiple switches between Humira® and ABP 501 (new high concentration formulation) compared with continued use of Humira® in participants with moderate to severe plaque psoriasis. This multi-center study is composed of two periods: A lead-in period of treatment with Humira® followed by a randomized two parallel arm period.

Timeline

Start

2021-10-04

Primary completion

2022-12-19

Completion

2022-12-19

Publications

• Yamauchi PS, Chow V, Mytych DT, Zhou M, Radziszewski W. Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis. Adv Ther. 2026 Jun;43(6):2795-2808. doi: 10.1007/s12325-026-03574-8. Epub 2026 Apr 9.

Drugs

Indications